Background
==========

Thiazide diuretics have remained important medications for the treatment of hypertension for over 50 years, since they became available in the late 1950s \[[@B1],[@B2]\]. Numerous clinical trials have shown the clinical efficacy of thiazides, as well as a reduction in cardiovascular morbidity and mortality, resulting from their blood pressure (BP)-lowering effect \[[@B3]-[@B5]\]. Most complications of thiazide therapy are related to their adverse-effect profile. It is well known that thiazides can reduce the excretion of calcium and uric acid, thereby leading to an increase in their plasma levels, and that these drugs increase potassium and magnesium excretion, potentially leading to hypokalemia and hypomagnesemia \[[@B6]\]. Low doses of thiazides, however, are usually tolerated and have been shown to improve quality-of-life measures \[[@B7]\]. Thiazides are now more commonly used at lower doses to minimize the potential harm of adverse effects. Recent reports thus recommend thiazide diuretics as first-line choices for the treatment of essential hypertension, as monotherapy or in combination with other agents \[[@B8],[@B9]\]. Trichlormethiazide, a thiazide diuretic, was introduced in 1960 and remains one of the most frequently used diuretics for treating hypertension in Japan \[[@B10]\]. While many studies have shown an important side effect of thiazides, i.e., adverse effects on electrolytes, very few data exist on plasma electrolyte levels in patients with trichlormethiazide treatment. To clarify whether adverse changes in plasma electrolyte levels are associated with trichlormethiazide is important for clinical practice. In this study, we examined changes in serum electrolyte levels of new users of generally prescribed doses of trichlormethiazide, of 1 mg or 2 mg per day, and compared them with each respective control (who had not received trichlormethiazide). We also examined changes in serum uric acid levels in addition to serum creatinine and urea nitrogen.

Methods
=======

Data source
-----------

This was a retrospective database study using the Nihon University School of Medicine (NUSM) Clinical Data Warehouse (CDW), which is a centralized data repository that integrates separate databases, such as an order entry database and a laboratory results database, from the hospital information systems at three hospitals affiliated to NUSM. The prescription database in the CDW contains information from over 0.4 million patients, and prescribing data are linked longitudinally to detailed clinical information such as patient demographics, diagnosis, and laboratory results data.

Study participants
------------------

Patients aged over 20 years who had been treated with antihypertensive agents (thiazide diuretic, β-blocker, calcium channel blocker (CCB), α-blocker, angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), vasodilator or centrally acting agent) for at least three months between Nov 1, 2004 and July 31, 2010, were identified for the study. Of 28,647 patients who fulfilled the above criteria, we identified 1404 patients with trichlormethiazide treatment. We compared new users of trichlormethiazide (1 mg or 2 mg per day) with a propensity-score matched sample of controls who had not used trichlormethiazide. New use of an antihypertensive agent was defined as prescription of the study drug, with no use of this drug in the 90 days preceding the date this prescription was filled (taken as the index date). We excluded patients who had received a potassium or sodium preparation, insulin, allopurinol, uricosuric drug or diuretic (loop, potassium-sparing or thiazide diuretic except for trichlormethiazide) during the study period. We also excluded patients whose serum creatinine level was more than 2 mg/dl before the index date. Because trichlormethiazide was often combined with other antihypertensive agents, such as a CCB, ARB or ACEI, we focused on combination therapy of trichlormethiazide, and excluded patients who had been treated with trichlormethiazide monotherapy. Consequently, all users of trichlormethiazide in this study had received combination therapy with one or more other antihypertensive agents prior to or on the date trichlormethiazide was initiated. In addition, patients who had received these combined agents during at least three months of trichlormethiazide coadministration were selected. The study cohorts thus included 99 new users of trichlormethiazide (1 mg/day) with 99 matched control patients, and 61 new users of trichlormethiazide (2 mg/day) with 61 matched control patients. The experimental protocol was approved by the Ethical Committee of Nihon University School of Medicine.

Exposure and measurements
-------------------------

The baseline measurement period (non-exposure period) was defined as the 60 days before the index date of any antihypertensive agent. The exposure period (outcome measurement period) was defined as between 1 and 3 months after the start of trichlormethiazide treatment in the trichlormethiazide cohort. Blood test data (serum sodium, potassium, uric acid, creatinine and urea nitrogen) were collected for each individual at the date nearest the index date in the baseline period, and at the date nearest to three months after the start of trichlormethiazide treatment in the exposure period. In trichlormethiazide users, the lag-time for starting treatment with trichlormethiazide from the start of treatment with other combined antihypertensive agents varied among individuals. Therefore, the exposure period in the control cohort was adjusted according to the matched pair in the trichlormethiazide cohort.

Data elements
-------------

For each individual, we collected information of patient demographics (age and sex), medical history, use of antihypertensive agents or other drugs, and laboratory results. Medical history included disease information of cerebrovascular disease (ICD10 codes, I60-I69), ischemic heart disease (I20-I25), other heart disease (I30-I52), liver disease (K70-K77), kidney disease (N00-N19), gout (M10), thyroid gland disorders (E00-E07), hyperlipidemia (E78.0-E78.5), and diabetes mellitus (E10-E14), which had been diagnosed in the 365 days preceding the first date the prescription of any antihypertensive agent was filled. This medical history also included the binary laboratory results of whether urinary protein was positive or not. We noted current users of antihypertensive agents (β-blocker, CCB, α-blocker, α+β-blocker, ACEI, ARB, or vasodilator), defined as patients who received them after the index date up to their outcome measurement. Past users were defined as patients who received drugs during the 90 days before the index date. We also noted past users of other drugs than antihypertensive agents, including steroids, lipid-lowering drugs, oral antihyperglycemic drugs, thyroid drugs and chemotherapeutic drugs.

Propensity score matching
-------------------------

We used propensity-score matching to reduce bias by balancing covariates between settings. The propensity score for each subject is obtained by fitting a logistic regression model that includes the predictor variable (i.e., users or non-users) as an outcome and all baseline covariates in Table [1](#T1){ref-type="table"}\[[@B11]\]. We used all these observed variables regardless of statistical significance. After the propensity score was constructed, we matched the propensity score of each patient with diabetes and without diabetes (a 1:1 match). A nearest-neighbor-matching algorithm with a \"greedy\" heuristic was used to match patients and the logit of their propensity score, with matching occurring if the difference in the logits of the propensity scores was less than 0.2 times the standard deviation (SD) of the scores (caliper width) \[[@B12]\]. This caliper of 0.2 SD of the logit of propensity score was suggested by Austin after an extensive simulation study \[[@B13]\]. We compared the prevalence of all baseline covariates after PS matching using a *t*-test for continuous variables and chi-squared tests for categorical data.

###### 

Baseline characteristics after propensity score matching

  Characteristic                    TCM users (1 mg/day) with matched controls   TCM users (2 mg/day) with matched controls                                        
  --------------------------------- -------------------------------------------- -------------------------------------------- -------- ------------- ------------- --------
  Exposure days (days, mean ± SD)   57.8 ± 14.8                                  \-                                                    63.9 ± 16.4   \-            
  Age (years, mean ± SD)            65.8 ± 13.5                                  66.4 ± 11.4                                  0.7476   67.5 ± 9.9    69.2 ± 11.2   0.3741
  Women                             54 (55%)                                     61 (62%)                                     0.3134   26 (43%)      27 (44%)      0.8551
  Medical History                                                                                                                                                  
   Diabetes mellitus                54 (55%)                                     57 (58%)                                     0.6675   42 (69%)      44 (72%)      0.6914
   Cerebrovascular diseases         33 (33%)                                     41 (41%)                                     0.2399   17 (28%)      11 (18%)      0.1964
   Ischemic heart diseases          19 (19%)                                     21 (21%)                                     0.7233   12 (20%)      11 (18%)      0.8169
   Other heart disease              42 (42%)                                     35 (35%)                                     0.3075   34 (56%)      36 (59%)      0.7143
   Liver disease                    22 (22%)                                     24 (24%)                                     0.7364   27 (44%)      25 (41%)      0.7143
   Kidney disease                   30 (30%)                                     28 (28%)                                     0.7548   21 (34%)      17 (28%)      0.4342
   Gout                             5 (5%)                                       5 (5%)                                       1        1 (2%)        1 (2%)        1
   Thyroid disorders                27 (27%)                                     31 (31%)                                     0.5322   23 (38%)      25 (41%)      0.7109
   Hyperlipidemia                   59 (60%)                                     56 (57%)                                     0.6657   50 (82%)      52 (85%)      0.6248
   COPD                             5 (5%)                                       4 (4%)                                       0.733    5 (8%)        3 (5%)        0.4645
   Proteinuria                      30 (30%)                                     32 (32%)                                     0.7592   22 (36%)      21 (34%)      0.8497
  Past drugs                                                                                                                                                       
   Chemotherapeutic drugs           1 (1%)                                       0 (0%)                                       0.3161   3 (5%)        3 (5%)        1
   Oral antihyperglycemic drugs     10 (10%)                                     13 (13%)                                     0.5058   11 (18%)      15 (25%)      0.3765
   Lipid-lowering drugs             30 (30%)                                     22 (22%)                                     0.1964   26 (43%)      23 (38%)      0.5796
   Steroids                         10 (10%)                                     7 (7%)                                       0.4467   9 (15%)       5 (8%)        0.2559
   Thyroid drugs                    3 (3%)                                       4 (4%)                                       0.7004   0 (0%)        0 (0%)        \-
  Current antihypertensive drugs                                                                                                                                   
   ARB                              70 (71%)                                     67 (68%)                                     0.6442   35 (57%)      34 (56%)      0.8551
   AECI                             21 (21%)                                     23 (23%)                                     0.7324   14 (23%)      15 (25%)      0.8316
   CCB                              81 (82%)                                     83 (84%)                                     0.7063   44 (72%)      45 (74%)      0.8385
   Beta-blocker                     14 (14%)                                     11 (11%)                                     0.5209   15 (25%)      13 (21%)      0.6668
   Alpha+beta-blocker               6(6%)                                        6 (6%)                                       1        3 (5%)        3 (5%)        1
   Alpha-blocker                    8 (8%)                                       14 (14%)                                     0.1748   9 (15%)       8 (13%)       0.7938
   Alpha-agonist                    0 (0%)                                       0 (0%)                                       \-       0 (0%)        0 (0%)        \-
   Vasodilator                      0 (0%)                                       1 (1%)                                       0.3161   0 (0%)        0 (0%)        \-

Data are numbers of individuals (%) unless otherwise stated. Abbreviations: TCM, trichlormethiazide; COPD, chronic obstructive pulmonary disease; ARB, angiotensin II receptor blocker; AECI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker.

Statistical analysis
--------------------

The *t*-test was used to compare the differences in means between the trichlormethiazide use group and the control group. All reported P values are two-sided, and P values of less than 0.05 were considered to indicate statistical significance. All analyses were performed with SAS software, version 9.2 (SAS Institute, Cary, NC).

Results
=======

Table [1](#T1){ref-type="table"} shows the characteristics of the trichlormethiazide cohorts of 1 mg and 2 mg daily dosage and corresponding control cohorts, after propensity-score matching. There were no statistically significant differences for all covariates between trichlormethiazide users and controls for both doses. The mean age was 66 years, and 55% of trichlormethiazide users of the 1 mg dose were female. In trichlormethiazide users of the 2 mg dose, the mean age was 68 years, and 43% of users were female. The mean exposure of trichlormethiazide of 1 mg and 2 mg users was 58 days and 64 days, respectively. In trichlormethiazide users of 1 mg and 2 mg doses, 82% and 72% were currently using a CCB, and 71% and 57% an ARB, respectively. These findings suggest that the major counterparts of trichlormethiazide combination therapy were CCBs or/and ARBs.

Table [2](#T2){ref-type="table"} shows the results of laboratory test values at baseline and during the exposure period. There were no statistically significant differences in the mean values for all tests between baseline and during the exposure period in control. In trichlormethiazide users, also, the mean values for all tests, except the following findings, showed no significant change between baseline and during the exposure period; mean serum sodium level during the exposure period was significantly lower than that at baseline in trichlormethiazide users of the 1 mg dose, whereas in trichlormethiazide users of the 2 mg dose, mean serum uric acid level during the exposure period was significantly higher than that at baseline. Serum urea nitrogen level also tended to increase. Mean serum levels for all tests, however, remained within normal limits during the exposure period in both trichlormethiazide users and controls.

###### 

Summary of serum chemical data

                          TCM users (1 mg/day) with matched controls                                      
  ----------------------- -------------------------------------------- ------------------- -------------- ----------------
  Urea nitrogen, mmol/L                                                                                   
   Baseline               5.83 ± 0.18                                  (5.47, 6.20)        5.54 ± 0.18    (5.18, 5.90)
   Exposure               6.10 ± 0.20                                  (5.72, 6.51)        5.53 ± 0.17    (5.19, 5.87)
  Creatinine, μmol/L                                                                                      
   Baseline               71.7 ± 1.9                                   (67.8, 75.6)        66.3 ± 2.2     (61.9, 70.7)
   Exposure               73.2 ± 2.3                                   (68.6, 77.8)        67.9 ± 2.5     (62.9, 72.9)
  Uric acid, μmol/L                                                                                       
   Baseline               337.4 ± 8.9                                  (319.7, 355.1)      316.0 ± 8.1    (300.0, 332.0)
   Exposure               349.6 ± 8.5                                  (332.7, 366.4)      316.8 ± 7.8    (301.3, 332.2)
  Sodium, mmol/L                                                                                          
   Baseline               142.0 ± 0.3                                  (141.5, 142.5)      141.8 ± 0.2    (141.3, 142.2)
   Exposure               141.1 ± 0.3\*                                (140.5, 141.7)      141.4 ± 0.3    (140.8, 141.9)
  Potassium, mmol/L                                                                                       
   Baseline               4.24 ± 0.04                                  (4.17, 4.32)        4.28 ± 0.04    (4.20, 4.35)
   Exposure               4.28 ± 0.04                                  (4.20, 4.36)        4.31 ± 0.04    (4.23, 4.39)
                                                                                                          
                          TCM users (2 mg/day) with matched controls                                      
                                                                                                          
  Laboratory Test         Users (N = 61)                               Controls (N = 61)                  
                          Mean ± SE                                    (95% CI)            Mean ± SE      (95% CI)
                                                                                                          
  Urea nitrogen, mmol/L                                                                                   
   Baseline               6.15 ± 0.24                                  (5.68, 6.62)        5.66 ± 0.21    (5.24, 6.09)
   Exposure               6.80 ± 0.27                                  (6.25, 7.34)        5.85 ± 0.22    (5.41, 6.29)
  Creatinine, μmol/L                                                                                      
   Baseline               73.4 ± 3.1                                   (67.2, 79.6)        68.1 ± 2.2     (63.7, 72.5)
   Exposure               77.7 ± 3.5                                   (70.7, 84.7)        70.3 ± 2.6     (65.1, 75.7)
  Uric acid, μmol/L                                                                                       
   Baseline               333.7 ± 11.1                                 (311.5, 355.8)      310.6 ± 9.3    (291.9, 329.1)
   Exposure               381.8 ± 11.0\*\*                             (359.7, 403.9)      327.0 ± 12.0   (303.0, 351.1)
  Sodium, mmol/L                                                                                          
   Baseline               141.8 ± 0.3                                  (141.2, 142.3)      141.9 ± 0.3    (141.2, 142.5)
   Exposure               141.6 ± 0.3                                  (141.0, 142.3)      141.6 ± 0.3    (141.0, 142.2)
  Potassium, mmol/L                                                                                       
   Baseline               4.27 ± 0.06                                  (4.16, 4.39)        4.32 ± 0.06    (4.21, 4.44)
   Exposure               4.13 ± 0.05                                  (4.03, 4.23)        4.36 ± 0.05    (4.27, 4.45)

\*P \< 0.05 vs. baseline. \*\*P \< 0.01 vs. baseline. Abbreviations: TCM, trichlormethiazide; SE, standard error; CI, confidence interval.

Figure [1](#F1){ref-type="fig"} shows the changes in laboratory test mean values during the exposure period compared with baseline. In trichlormethiazide users of the 1 mg dose, all tests showed no statistically significant change from baseline to during the exposure period in comparison with control, whereas in trichlormethiazide users of the 2 mg dose, the reduction of serum potassium level and the elevation of serum uric acid level were significant in comparison with control.

![**Mean changes in laboratory test values during the exposure period from baseline**. Data represent mean ± standard error of trichlormethiazide users (open bars) and controls (closed bars). Δ indicates the change in mean serum value during exposure period from baseline. \*P \< 0.01 vs. Control.](1475-2840-10-45-1){#F1}

Discussion
==========

In this study, we found that the reduction of serum potassium level and the elevation of serum uric acid level in trichlormethiazide users of the 2 mg dose were significantly greater than those in trichlormethiazide non-users, but these adverse events did not occur in trichlormethiazide users of the 1 mg dose. Many researchers have reported potential adverse events associated with thiazide therapy, including diuretic-induced hypokalemia and increased serum uric acid \[[@B6],[@B14]\]. Supporting these reports, our study demonstrated some adverse effects, including decreased serum potassium and increased serum uric acid, with trichlormethiazide, the same as with other thiazides. Clinical evidence suggests similar antihypertensive efficacy between low and high doses, with lower complication rates with low doses \[[@B15],[@B16]\]. Franse et al demonstrated a trend suggesting that higher doses of thiazide diuretics correlate with greater reduction in serum potassium level and increased risk of hypokalemia \[[@B17]\]. Hypertension therapeutics in recent years, have thus shifted towards lower doses of thiazides. Because our study was not designed to compare the cohorts with 1 mg and 2 mg doses of trichlormethiazide, we cannot strictly conclude whether the adverse effects on serum potassium and uric acid are dose-dependent or not. However, our study, showing an absence of significant adverse effects in the 1 mg dose of trichlormethiazide users, recommends lower doses for both trichlormethiazide monotherapy and combination therapy, the same as for other thiazides.

A few studies have suggested potential adverse effects of treatment with trichlormethiazide on serum uric acid. The National Intervention Cooperative Study in Elderly Hypertensives (NICS-EH) showed that the increase in serum uric acid level in the trichlormethiazide group was significantly different from that in the nicardipine group \[[@B18]\]. Ishimitsu et al showed that serum uric acid level was significantly higher at the end of combined treatment with trichlormethiazide than following treatment with olmesartan alone \[[@B19]\]. These studies, however, showed no significant reduction of serum potassium level with trichlormethiazide treatment. It is difficult to accurately compare the findings with regard to potassium wasting because of variations in study design and cofounding variables between our study and those trials. This study focused on combination therapy and compared trichlormethiazide users and non-users because a thiazide diuretic is often combined with a CCB, ARB or ACEI in clinical practice in Japan \[[@B10]\]. When the renin-angiotensin-aldosterone system is blocked sufficiently, thiazide diuretics enhance BP lowering and increase the proportion of patients achieving goal BP \[[@B6],[@B20]\]. Combination therapy of these agents with a thiazide diuretic may cancel the adverse effects associated with diuretic therapy, including diuretic-induced hypokalemia, hyperglycemia, and increased serum uric acid \[[@B21],[@B22]\]. In this study, we used propensity-score matching to balance the population of users of other combined antihypertensive agents, a potential confounding variable, between trichlormethiazide users and non-users, and thereby found a significant reduction of serum potassium level in trichlormethiazide users of the 2 mg dose compared with non-users, whereas in the comparison between treatment with 2 mg trichlormethiazide and baseline, serum potassium level tended to decrease, but not significantly. This finding may be biased by various confounders, including other combined agents that would offset the adverse effects of diuretics.

In this study, serum sodium level during treatment with trichlormethiazide at the 1 mg dose was lower than that at baseline, but this negative skew was not seen at the 2 mg dose. This finding may also be confounded by other variables because this result was not compared with that of controls. The discrepancy between 1 mg and 2 mg users of trichlormethiazide could be explained in part by differences in the population studied. Thiazide-induced hyponatremia is less well characterized. It usually occurs within 2 weeks after the initiation of treatment with a thiazide diuretic \[[@B23]\], whereas large trials using long-term thiazides showed a lack of generalized reduction in sodium concentration \[[@B24]\]. Risk factors for the development of hyponatremia include older age, female sex, and low body weight \[[@B23],[@B25]\]. Previously, the NICE-EH trial showed a significant reduction of serum sodium value in the trichlormethiazide group in comparison with the nicardipine group \[[@B18]\]. Trichlormethiazide users in the NICE-EH trial and our study at the 1 mg dose would be similar with respect to unmeasured potential confounders that might differ between 1 mg and 2 mg users of trichlormethiazide. These confounding variables may have a greater impact on the results than trichlormethiazide, because the reduction of serum sodium level in this study was not significant in users compared to non-users of trichlormethiazide. Of the measured variables, the population with other combined antihypertensive agents differed between 1 mg and 2 mg users of trichlormethiazide, and may affect the difference in serum sodium values between the groups. Although it is unclear whether the reduction in sodium concentration in our study was induced by trichlormethiazide or/and other antihypertensive agents, trichlormethiazide is often used for combination therapy with other antihypertensive drugs in real-world practice. Therefore, when prescribing a thiazide, regular checks of electrolyte levels should be performed, especially at baseline and within 2 weeks after initiating therapy.

Our study has some limitations. First, the nature of the observational study involved inherent issues of selection bias and confounding, which are commonly encountered in observational studies estimating the effect of a treatment by comparing outcomes for non-randomized subjects. Although we used rigorous statistical methods to balance potential confounding variables across trichlormethiazide and control users, including propensity-score matching, their ability to control for differences was limited to variables for which they were available or measurable. Nonetheless, the results of well-designed observational studies (with either a cohort or a case-control design) were reported not to systematically overestimate the magnitude of the effects of treatment as compared with those of randomized-controlled trials on the same issue \[[@B26]\]. Second, there is also the possibility of inaccuracy of information in the database (e.g., misclassification of exposure and outcome, ascertainment bias, etc). Prescription claims data and medical records are considered by many to be the gold standard for measuring drug exposure and for capturing intermediate and final outcomes, respectively \[[@B27]\]. NUSM\'s CDW used in this study may combine the best of both worlds by linking a prescription database to detailed medical information, and is suitable for pharmacoepidemiologic research. Several epidemiological studies examining the effects of antihypertensive drugs on glucose and lipid metabolism using NUSM\'s CDW have been published to date \[[@B28],[@B29]\].

Conclusions
===========

In this study, we observed some adverse effects, including decreased serum potassium and increased serum uric acid, with trichlormethiazide, as with other thiazides. These findings support the experience noted in clinical practice that regular checks of electrolyte levels should be performed prior to and after thiazide initiation. In addition, our study suggested that a lower dose of trichlormethiazide may minimize the adverse effects, supporting the current trend in hypertension therapeutics to shift towards lower doses of thiazides. However, the findings of our study, based on a non-randomized design, call for further studies, such as similar analyses of larger and more recent databases, longitudinal studies for a long-term period, and randomized clinical trials for confirmation.
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